

1           **Out-of-Pocket Spending Within 90 Days of Discharge from COVID-19 Hospitalization**

2  
3           Kao-Ping Chua, MD, PhD<sup>a,b</sup>, Rena M. Conti, PhD<sup>c</sup>, Nora V. Becker, MD, PhD<sup>d</sup>

4  
5           **Affiliations:**

6           <sup>a</sup>Department of Pediatrics, Susan B. Meister Child Health Evaluation and Research Center,  
7           University of Michigan Medical School, Ann Arbor

8  
9           <sup>b</sup>Department of Health Management and Policy, University of Michigan School of Public Health,  
10           Ann Arbor

11  
12           <sup>c</sup>Department of Markets, Public Policy, And Law, Institute for Health System Innovation and  
13           Policy, Questrom School of Business, Boston University, Boston

14  
15           <sup>d</sup>Department of Internal Medicine, Division of General Medicine, University of Michigan  
16           Medical School, Ann Arbor

17  
18           **Address correspondence to:** Kao-Ping Chua, MD, PhD, 300 North Ingalls St, SPC 5456, Room  
19           6E18, Ann Arbor, Michigan 48109-5456. E-mail: [chuak@med.umich.edu](mailto:chuak@med.umich.edu). Phone: 734-615-  
20           8169

21  
22           **Conflicts of interest:** The authors have no conflicts of interest to disclose.

23  
24           **Financial disclosures:** none

25  
26           **Word count:** 1199

27  
28           **Date:** June 15, 2021

29

## ABSTRACT

30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58

**INTRODUCTION:** Millions of U.S. patients have been hospitalized for COVID-19. After discharge, these patients often have extensive health care needs, but out-of-pocket burden for this care is poorly described. We assessed out-of-pocket spending within 90 days of discharge from COVID-19 hospitalization among privately insured and Medicare Advantage patients.

**METHODS:** In May 2021, we conducted a cross-sectional analysis of the IQVIA PharMetrics<sup>®</sup> Plus for Academics Database, a national de-identified claims database. Among privately insured and Medicare Advantage patients hospitalized for COVID-19 between March-June 2020, we calculated mean out-of-pocket spending for care within 90 days of discharge. For context, we repeated analyses for patients hospitalized for pneumonia.

**RESULTS:** Among 1,465 COVID-19 patients included, 516 (35.2%) and 949 (64.8%) were covered by private insurance and Medicare Advantage plans. Among these patients, mean (SD) post-discharge out-of-pocket spending was \$534 (1,045) and \$680 (1,360); spending exceeded \$2,000 for 7.0% and 10.3%. Compared with pneumonia patients, mean post-discharge out-of-pocket spending among COVID-19 patients was higher among the privately insured (\$534 vs \$445) and lower among Medicare Advantage patients (\$680 vs \$918).

**CONCLUSIONS:** For the privately insured, post-discharge out-of-pocket spending was higher among patients hospitalized for COVID-19 than among patients hospitalized for pneumonia. The opposite was true for Medicare Advantage patients, potentially because insurer cost-sharing waivers for COVID-19 treatment covered the costs of some post-discharge care, such as COVID-19 readmissions. Nonetheless, given the high volume of U.S. COVID-19 hospitalizations to date, our findings suggest a large number of Americans have experienced substantial financial burden for post-discharge care.

## 59 INTRODUCTION

60 Millions of U.S. patients have been hospitalized for coronavirus disease 2019 (COVID-  
61 19).<sup>1</sup> After discharge, these patients often have extensive health care needs.<sup>2-4</sup> However, out-of-  
62 pocket burden for this care has been poorly described. Addressing this gap in knowledge is  
63 crucial, as substantial out-of-pocket burden for post-discharge care might exacerbate other  
64 financial stresses experienced by patients hospitalized for COVID-19, such as loss of  
65 employment.<sup>4</sup> Using national claims data from privately insured and Medicare Advantage  
66 patients, we assessed out-of-pocket spending within 90 days of discharge from COVID-19  
67 hospitalizations during March-June 2020.

## 69 METHODS

70 *Study sample.* In May 2021, we conducted a cross-sectional analysis of the IQVIA  
71 PharMetrics<sup>®</sup> Plus for Academics Database, which contains medical and pharmacy claims from  
72 de-identified patients in all U.S. states. Data included 7.7 million patients covered by fully-  
73 insured private plans and 1.0 million patients covered by Medicare Advantage plans in 2020.  
74 Claims through September 30, 2020 were available at the time of analysis. Because data were  
75 de-identified, the Institutional Review Board of the University of Michigan Medical School  
76 exempted analyses from human subjects review.

78 We identified hospitalizations for privately insured and Medicare Advantage patients that  
79 had a primary diagnosis of COVID-19 (ICD-10-CM diagnosis code U071) and that began and  
80 ended between March 1-June 30, 2020. We limited analyses to each patient's first hospitalization  
81 during this period. We excluded patients without continuous medical and pharmacy coverage

82 during the 90 days after discharge, patients whose plan was the secondary insurer, and patients  
83 with missing out-of-pocket spending data on any claim during the 90 days after discharge.

84  
85 *Measures.* We calculated mean out-of-pocket spending (sum of deductibles, co-  
86 insurance, and co-payments) across all claims during the 90 days after discharge. Additionally,  
87 we calculated mean out-of-pocket spending for 14 service categories: additional hospitalizations,  
88 nursing facility admissions, outpatient (e.g., office visits), emergency department visits,  
89 radiology, laboratory, diagnostic/therapeutic procedures (e.g., colonoscopy, surgery),  
90 physical/occupational/speech/respiratory therapy, home health/hospice, transportation, clinician-  
91 administered medications (e.g., infusions), durable medical equipment and supplies, pharmacy-  
92 dispensed prescriptions, and miscellaneous (**Appendix**). For context, we repeated analyses  
93 among patients hospitalized for bacterial pneumonia. These patients met similar inclusion and  
94 exclusion criterion and did not overlap with the main sample.

95  
96 *Statistical analyses.* Within payer types, we compared post-discharge out-of-pocket  
97 spending between COVID-19 and pneumonia patients using a one-part generalized linear model  
98 with a log link and Poisson variance function, chosen based on the modified Park test.<sup>5</sup> Models  
99 adjusted for age group, sex, Census region of residence, and month of admission. Analyses used  
100 SAS 9.4, Stata 15.1 MP, and two-sided hypothesis tests with  $\alpha = 0.05$ .

101  
102 **RESULTS**

103 Of 2,275 COVID-19 patients meeting inclusion criteria, 810 (35.8%) were excluded,  
104 leaving 1,465 patients. **Table 1** displays sample characteristics. Overall, 516 (35.2%) and 949  
105 (64.8%) patients were covered by private insurance and Medicare Advantage plans.

106           Among privately insured patients, mean (SD) post-discharge out-of-pocket spending was  
107 \$534 (1,045). For 36 (7.0%) and 15 (2.9%) patients, this spending exceeded \$2,000 and \$4,000.  
108 Service categories accounting for the most out-of-pocket spending were pharmacy-dispensed  
109 prescriptions (\$130; 24.4% of out-of-pocket spending) and hospitalizations (\$111; 20.8%).  
110 Among Medicare Advantage patients, mean post-discharge out-of-pocket spending was \$680  
111 (1,360). For 98 (10.3%) and 34 (3.6%) patients, this spending exceeded \$2,000 and \$4,000.  
112 Service categories accounting for the most out-of-pocket spending were hospitalizations (\$183;  
113 27.0%) and nursing facility admissions (\$126; 18.6%) (**Table 2**). Among privately insured and  
114 Medicare Advantage patients, 43.5% and 40.3% of out-of-pocket spending for pharmacy-  
115 dispensed prescriptions was for anticoagulants, diabetes drugs (e.g., insulin and sulfonylureas),  
116 and bronchodilators. In both populations, these medication classes accounted for the 3 highest  
117 shares of out-of-pocket spending for pharmacy-dispensed prescriptions.

118  
119           **Table 1** displays characteristics of the 1,374 patients hospitalized for pneumonia included  
120 in analyses. Among the 245 privately insured pneumonia patients, mean (SD) post-discharge out-  
121 of-pocket spending was \$450 (924), compared with \$534 among COVID-19 patients (adjusted  
122 difference: -\$131, 95% CI: -\$135, -\$128). Among the 1,129 Medicare Advantage patients, mean  
123 (SD) post-discharge out-of-pocket spending was \$918 (1,263), compared with \$680 among  
124 COVID-19 patients (adjusted difference: \$291, 95% CI: \$288, \$294). Among 370 Medicare  
125 Advantage patients with additional hospitalizations after a pneumonia hospitalization, 306  
126 (82.7%) had out-of-pocket spending for the additional hospitalizations. Among 206 Medicare  
127 Advantage patients with additional hospitalizations after a COVID-19 hospitalization, 141  
128 (68.1%) had out-of-pocket spending for the additional hospitalizations.

129 **DISCUSSION**

130           During the 90 days after COVID-19 hospitalization, privately insured and Medicare  
131 Advantage patients paid an average of \$534 and \$680 for health care; 7.0% and 10.3% of  
132 patients paid more than \$2,000. For privately insured patients, prescriptions and additional  
133 hospitalizations accounted for the highest shares of out-of-pocket spending. For Medicare  
134 Advantage patients, additional hospitalizations and nursing facility admissions accounted for the  
135 highest shares.

136  
137           For the privately insured, post-discharge out-of-pocket spending was higher among  
138 patients hospitalized for COVID-19 than among patients hospitalized for pneumonia. Perhaps  
139 surprisingly, the opposite was true for Medicare Advantage patients. A potential explanation is  
140 that some post-discharge care for COVID-19 patients, including readmissions for COVID-19,  
141 were covered by insurer cost-sharing waivers for COVID-19 treatment.<sup>6</sup> In support of this  
142 possibility, Medicare Advantage patients who had additional hospitalizations after a COVID-19  
143 hospitalization were less likely to have out-of-pocket spending for the additional hospitalizations  
144 compared with pneumonia patients. As many insurers allowed their cost-sharing waivers to  
145 expire in early 2021<sup>7</sup>, post-discharge out-of-pocket spending among patients hospitalized for  
146 COVID-19 could now be higher than among study patients.

147  
148           Even if out-of-pocket spending after COVID-19 hospitalization is not greater than for  
149 other conditions, our findings suggest a large number of Americans have experienced substantial  
150 post-discharge out-of-pocket spending given the volume of COVID-19 hospitalizations to date.  
151 To illustrate this point, national data estimate that 2.25 million COVID-19 hospitalizations

152 occurred between August 1, 2020 and June 13, 2021.<sup>1</sup> If 1 in 14 hospitalizations resulted in post-  
153 discharge out-of-pocket spending exceeding \$2,000 – the rate for privately insured patients in  
154 our study – this would translate to roughly 160,000 hospitalizations and more than \$320 million  
155 billed to patients for post-discharge care. Importantly, the expiration of insurer cost-sharing  
156 waivers means that many patients will now be billed for the COVID-19 hospitalization itself,  
157 adding further financial burden beyond that associated with post-discharge care. Consequently,  
158 monitoring the financial health of patients hospitalized for COVID-19 is a key policy priority  
159 going forward.

160

161 This study has limitations. First, analyses only captured the immediate period after  
162 COVID-19 hospitalization. Second, the post-discharge period in this study occurred during the  
163 early stages of the pandemic, when health care utilization decreased sharply owing partly to  
164 social distancing measures.<sup>8</sup> Post-discharge utilization, and therefore out-of-pocket spending,  
165 might be higher now that utilization is rebounding. Third, this study required hospital discharge  
166 by June 30, 2020 because a 90-day post-discharge period was needed and claims were complete  
167 only through September 30, 2020 at the time of analysis. While necessary, this decision excluded  
168 patients with prolonged hospitalizations who may require intensive post-discharge care.  
169 Consequently, analyses likely underestimate out-of-pocket burden among all patients  
170 hospitalized for COVID-19. Finally, patients may not be fully representative of the entire  
171 privately insured and Medicare Advantage population.

172

173

174

175 **CONCLUSIONS**

176           In this national cohort of 1,465 patients hospitalized for COVID-19 during March-June  
177 2020, out-of-pocket spending within 90 days of discharge exceeded \$2,000 for 1 in 14 privately  
178 insured patients and 1 in 10 Medicare Advantage patients. Future studies should repeat analyses  
179 among patients more recently hospitalized for COVID-19 using longer follow-up periods.

180 **ACKNOWLEDGEMENTS**

181 **Author Contributions:** Dr. Chua had full access to all of the data in the study and takes  
182 responsibility for the integrity of the data and the accuracy of the data analysis.

183  
184 Kao-Ping Chua: Conceptualization, Methodology, Software, Formal analysis, Writing – original  
185 draft, Data curation, Writing – review and editing, Visualization, Funding acquisition

186  
187 Rena Conti: Conceptualization, Methodology, Formal analysis, Writing – review and editing

188  
189 Nora Becker: Conceptualization, Methodology, Formal analysis, Writing – review and editing,  
190 Supervision.

191  
192 **Funding source:** Funding for purchasing IQVIA data was partially provided by the Susan B.  
193 Meister Child Health Evaluation and Research Center at the University of Michigan Medical  
194 School. Dr. Chua’s effort is supported by a career development award from the National Institute  
195 on Drug Abuse (grant number 1K08DA048110-01). The funders played no role in the design and  
196 conduct of the study; collection, management, analysis, and interpretation of the data;  
197 preparation, review, or approval of the manuscript; and decision to submit the manuscript for  
198 publication

199  
200 **Conflicts of interest:** The authors have no conflicts of interest to disclose.  
201

202   **REFERENCES**

- 203   1.   Centers for Disease Control and Prevention. Covid Data Tracker. [Internet]. 2021;  
204       <https://covid.cdc.gov/covid-data-tracker/#new-hospital-admissions>. Accessed June 3,  
205       2021.
- 206   2.   Lavery AM, Preston LE, Ko JY, et al. Characteristics of Hospitalized Covid-19 Patients  
207       Discharged and Experiencing Same-Hospital Readmission - United States, March-August  
208       2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(45):1695-1699.
- 209   3.   Weerahandi H, Hochman KA, Simon E, et al. Post-Discharge Health Status and  
210       Symptoms in Patients with Severe Covid-19. *J Gen Intern Med.* 2021;36(3):738-745.
- 211   4.   Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes  
212       among Patients Hospitalized with Covid-19. *Ann Intern Med.* 2021;174(4):576-578.
- 213   5.   Buntin MB, Zaslavsky AM. Too Much Ado About Two-Part Models and  
214       Transformation? Comparing Methods of Modeling Medicare Expenditures. *Journal of*  
215       *Health Economics.* 2004;23:525-542.
- 216   6.   America's Health Insurance Plans. Health Insurance Providers Respond to Coronavirus  
217       (Covid-19). [Internet]. 2021; [https://www.ahip.org/health-insurance-providers-respond-](https://www.ahip.org/health-insurance-providers-respond-to-coronavirus-covid-19)  
218       [to-coronavirus-covid-19](https://www.ahip.org/health-insurance-providers-respond-to-coronavirus-covid-19). Accessed May 25, 2021.
- 219   7.   Appleby J. Time to Say Goodbye to Some Insurers' Waivers for Covid Treatment Fees.  
220       [Internet]. 2021; [https://khn.org/news/article/time-to-say-goodbye-to-some-insurers-](https://khn.org/news/article/time-to-say-goodbye-to-some-insurers-waivers-for-covid-treatment-fees/)  
221       [waivers-for-covid-treatment-fees/](https://khn.org/news/article/time-to-say-goodbye-to-some-insurers-waivers-for-covid-treatment-fees/). Accessed May 25, 2021.
- 222   8.   Cox C, Amin K, Kamal R. How Have Health Spending and Utilization Changed During  
223       the Coronavirus Pandemic? 2021; [https://www.healthsystemtracker.org/chart-](https://www.healthsystemtracker.org/chart-collection/how-have-healthcare-utilization-and-spending-changed-so-far-during-the-coronavirus-pandemic/#item-start)  
224       [collection/how-have-healthcare-utilization-and-spending-changed-so-far-during-the-](https://www.healthsystemtracker.org/chart-collection/how-have-healthcare-utilization-and-spending-changed-so-far-during-the-coronavirus-pandemic/#item-start)  
225       [coronavirus-pandemic/#item-start](https://www.healthsystemtracker.org/chart-collection/how-have-healthcare-utilization-and-spending-changed-so-far-during-the-coronavirus-pandemic/#item-start). Accessed June 9, 2021.

226

**Table 1.** Characteristics of patients hospitalized for COVID-19 and pneumonia between March-June 2020, IQVIA PharMetrics® Plus for Academics Database

	COVID-19 (n= 1,465) <sup>a</sup>		Pneumonia (n = 1,374) <sup>b</sup>	
	Private insurance	Medicare Advantage	Private insurance	Medicare Advantage
<b>Number of patients</b>	516	949	245	1,129
<b>Age in years</b>				
0-17	6 (1.2%)	0 (0.0%)	17 (6.9%)	0 (0.0%)
18-34	33 (6.4%)	4 (0.4%)	25 (10.2%)	0 (0.0%)
35-54	226 (43.8%)	44 (4.6%)	86 (35.1%)	67 (5.9%)
55-64	202 (39.1%)	102 (10.7%)	99 (40.4%)	168 (14.9%)
65-74	45 (8.7%)	319 (33.6%)	14 (5.7%)	379 (33.6%)
75-85	3 (0.6%)	319 (33.6%)	4 (1.6%)	350 (31.0%)
≥ 86	1 (0.2%)	161 (17.0%)	0 (0.0%)	165 (14.6%)
<b>Sex</b>				
Male	322 (62.4%)	411 (43.3%)	121 (49.4%)	532 (47.1%)
Female	194 (37.6%)	538 (56.7%)	124 (50.6%)	597 (52.9%)
<b>Region</b>				
Northeast	150 (29.1%)	467 (49.2%)	25 (10.2%)	146 (12.9%)
Midwest	122 (23.6%)	308 (32.5%)	56 (22.9%)	617 (54.7%)
South	165 (32.0%)	110 (11.6%)	113 (46.1%)	275 (24.4%)
West	76 (14.7%)	62 (6.5%)	51 (20.8%)	90 (8.0%)
<b>Admission month</b>				
March	85 (48.1%)	143 (54.7%)	117 (24.1%)	447 (23.1%)
April	248 (18.8%)	519 (20.7%)	59 (16.7%)	261 (21.8%)
May	97 (16.7%)	196 (9.6%)	41 (11.4%)	246 (15.5%)
June	86 (16.7%)	91 (9.6%)	28 (11.4%)	175 (15.5%)
<b>Mean length of stay (SD)</b>	7.9 (8.2)	8.9 (7.9)	4.2 (4.2)	4.6 (3.4)
<b>Any intensive care unit utilization<sup>a</sup></b>	239 (46.3%)	339 (35.7%)	86 (35.1%)	437 (38.7%)

<sup>a</sup>Among 2,275 patients with an initial hospitalization for COVID-19 between March 1-June 30, 2020, 747 were excluded because they lacked continuous enrollment during the 90 days after discharge, 54 because their insurance was not primary, and 8 because of missing data for out-of-pocket spending. We excluded 1 additional patient owing to the occurrence of a hospitalization that had not resulted in discharge by September 30, 2020 (raising the possibility that out-of-pocket spending for this hospitalization was not fully observed). In total, 810 patients were excluded, leaving 1,465 COVID-19 patients.

<sup>b</sup>We identified 1,810 patients who had a hospitalization with a primary diagnosis code for bacterial pneumonia (ICD-10-CM diagnosis code J13-J18) and no secondary diagnosis code for COVID-19 (U017) between March 1-June 30, 2020, and who were not in the sample of 1,465 COVID-19 patients. Of the 1,813 patients, 365 were excluded because they lacked continuous enrollment during the 90 days after discharge, 47 because their insurance was not primary, 22 because of missing data for out-of-pocket spending, and 2 because they had a hospitalization that had not resulted in discharge by September 30, 2020. In total, 436 patients were excluded, leaving 1,374 pneumonia patients.

<sup>c</sup>Defined as having at least one claim during the hospitalization with a revenue code for intensive care unit (0200-0209) or coronary care unit (0210-0219).

**Table 2.** Out-of-pocket spending for health care in the 90 days after COVID-19 hospitalization, IQVIA PharMetrics® Plus for Academics Database

Service category <sup>a</sup>	Private insurance (n = 516)					Medicare Advantage (n = 949)				
	No. patients with ≥1 claim (% patients in sample)	Mean (SD) OOP spending per patient in sample	% of all OOP spending	No. patients with OOP spending (% patients in sample)	Mean (SD) OOP spending among patients with OOP spending	No. patients with ≥1 claim (% patients in sample)	Mean (SD) OOP spending per patient in sample	% of all OOP spending	No. patients with OOP spending (% patients in sample)	Mean (SD) OOP spending among patients with OOP spending
Hospitalization	56 (10.9%)	\$111 (638)	20.8%	35 (6.8%)	\$1634 (1896)	206 (21.7%)	\$183 (824)	27.0%	141 (14.9%)	\$1235 (1815)
Nursing facility	2 (0.4%)	\$0 (12)	0.1%	1 (0.2%)	\$281 (NA)	221 (23.3%)	\$126 (698)	18.6%	128 (13.5%)	\$936 (1695)
Outpatient services	450 (87.2%)	\$44 (100)	8.2%	223 (43.2%)	\$101 (132)	797 (84.0%)	\$36 (57)	5.2%	497 (52.4%)	\$68 (64)
ED visits	56 (10.9%)	\$31 (190)	5.9%	25 (4.8%)	\$647 (597)	183 (19.3%)	\$13 (49)	1.9%	103 (10.9%)	\$121 (95)
Radiology tests	223 (43.2%)	\$65 (239)	12.2%	120 (23.3%)	\$280 (431)	404 (42.6%)	\$36 (166)	5.3%	241 (25.4%)	\$142 (30)
Laboratory tests	320 (62.0%)	\$41 (207)	7.8%	139 (26.9%)	\$154 (377)	632 (66.6%)	\$7 (20)	1.0%	282 (29.7%)	\$23 (3)
Procedures	188 (36.4%)	\$58 (300)	10.9%	100 (19.4%)	\$301 (628)	485 (51.1%)	\$97 (430)	14.2%	271 (28.6%)	\$338 (7)
PT, OT, ST, RT	37 (7.2%)	\$9 (75)	1.7%	16 (3.1%)	\$292 (323)	114 (12.0%)	\$9 (50)	1.3%	58 (6.1%)	\$141 (1)
Home health and hospice	76 (14.7%)	\$6 (72)	1.1%	10 (1.9%)	\$290 (456)	192 (20.2%)	\$3 (14)	0.4%	66 (7.0%)	\$38 (4)
Transportation	11 (2.1%)	\$4 (65)	0.8%	4 (0.8%)	\$526 (595)	162 (17.1%)	\$33 (186)	4.8%	98 (10.3%)	\$319 (49)
Administered medications <sup>b</sup>	98 (19.0%)	\$6 (62)	1.1%	38 (7.4%)	\$78 (216)	214 (22.6%)	\$26 (259)	3.8%	73 (7.7%)	\$332 (88)
DME and supplies	476 (92.2%)	\$12 (51)	2.3%	55 (10.7%)	\$114 (115)	906 (95.5%)	\$10 (61)	1.5%	179 (18.9%)	\$56 (13)
Pharmacy <sup>c</sup>	459 (89.0%)	\$130 (261)	24.4%	420 (81.4%)	\$160 (282)	837 (88.2%)	\$87 (212)	12.9%	649 (68.4%)	\$128 (24)
Miscellaneous	179 (34.7%)	\$15 (131)	2.8%	31 (6.0%)	\$253 (480)	381 (40.1%)	\$14 (118)	2.1%	66 (7.0%)	\$207 (40)
<b>Any service category</b>	<b>510 (98.8%)</b>	<b>\$534 (1045)</b>	<b>100.0%</b>	<b>453 (87.8%)</b>	<b>\$608 (1095)</b>	<b>939 (98.9%)</b>	<b>\$680 (1360)</b>	<b>100.0%</b>	<b>868 (91.5%)</b>	<b>\$743 (140)</b>

OOP – out-of-pocket; ED – emergency department; PT – physical therapy; OT – occupational therapy; ST – speech therapy; RT – respiratory therapy; DME – durable medical equipment; NA: not-applicable

<sup>a</sup>These service categories were based on the Agency for Healthcare Research and Quality Clinical Classification Software algorithm for procedures, v2020-1 (available at [https://www.hcup-us.ahrq.gov/toolssoftware/ccs\\_svcsproc/ccssvcsproc.jsp](https://www.hcup-us.ahrq.gov/toolssoftware/ccs_svcsproc/ccssvcsproc.jsp)). See Appendix for details.

<sup>b</sup>Administered medications refer to medications administered by clinicians, such as injections and infusions at visits

<sup>c</sup>Includes prescriptions dispensed at pharmacies